Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer
George Pentheroudakis, Vassiliki Kotoula, George Kouvatseas, et al.
Clinical Breast Cancer (2014) Vol. 14, Iss. 5, pp. 330-338
Closed Access | Times Cited: 11

Showing 11 citing articles:

Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT, MEK and ERK pathways in VEGF-stimulated human umbilical vein endothelial cells
Hsien‐Kuo Chin, Chi‐Ting Horng, Yi‐Shan Liu, et al.
Oncology Reports (2018)
Open Access | Times Cited: 72
SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression
Ning Dou, Dong Yang, Shijun Yu, et al.
Cell Proliferation (2018) Vol. 51, Iss. 5
Open Access | Times Cited: 45
Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy
Yu Yao, Wei Cai, Chong-Gang Pei, et al.
Biochemical and Biophysical Research Communications (2015) Vol. 458, Iss. 4, pp. 913-919
Closed Access | Times Cited: 42
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Alexander Hein, Diether Lambrechts, Gϋnter von Minckwitz, et al.
International Journal of Cancer (2015) Vol. 137, Iss. 12, pp. 2981-2988
Open Access | Times Cited: 31
Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
Yu Yao, Jing Yu, Chong Gang Pei, et al.
PubMed (2015) Vol. 8, Iss. 9, pp. 10355-64
Closed Access | Times Cited: 30
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab
George Pentheroudakis, Leonidas Mavroeidis, Kyriaki Papadopoulou, et al.
Clinical Colorectal Cancer (2019) Vol. 18, Iss. 4, pp. e370-e384
Closed Access | Times Cited: 24
Dysregulation of splicing variants and spliceosome components in breast cancer
Manuel D. Gahete, Natalia Hermán‐Sánchez, Antonio C. Fuentes-Fayos, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 9, pp. R123-R142
Open Access | Times Cited: 12
A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling
Yongrui Liu, Yuan He, Feifei Yang, et al.
Science China Life Sciences (2017) Vol. 60, Iss. 2, pp. 202-214
Closed Access | Times Cited: 13
JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances tantitumor function in a Fas/FasL signal-independent pathway
Yang Liu, Yue-ru Wang, Guang-hui Ding, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 4425-4433
Open Access | Times Cited: 12
Powerful quantifiers for cancer transcriptomics
Dumitru A. Iacobaş
World Journal of Clinical Oncology (2020) Vol. 11, Iss. 9, pp. 679-704
Open Access | Times Cited: 12
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer
Makoto Nishio, Shinji Atagi, Kōichi Goto, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 6, pp. 1167-1184
Open Access | Times Cited: 4
Page 1

Scroll to top